136112-01-1CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1OYYAZJTUGSQOFHG-RZFXJYHSSA-N136112-01-1Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
VerwendenSalmeterol-fluticasone combination as Adoair, dry powder inhlaler/pressured metered-dose inhaler formulation for bronchial asthma, its benefit or demerits as device for inhalation drug delivery system in pharmacokinetics/pharmacodynamics at lung or peripheral bronchi, indications and usage of aerochamber, and clinical efficacy and safety in asthma control.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…